Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis
暂无分享,去创建一个
G. Gores | V. Mazzaferro | M. Falconi | R. Miceli | S. Partelli | T. Masui | T. Cheung | E. Thiis-Evensen | H. Petrowsky | P. Clavien | J. Lerut | T. Musholt | P. Dutkowski | C. Rosen | C. Kim-Fuchs | A. Perren | M. Schneider | D. Eshmuminov | K. Lehmann | P. Line | M. Grąt | L. Sher | P. Husen | C. Sposito | L. Tanno | R. Robles-Campos | Mary Lo | T. Schreckenbach | N. Bouzakri | S. Barat | D. Morris | Debora J Studer | Víctor López López | Oana Lozan | Helga Oehler | Peri Husen | Nabila Bouzakri
[1] S. Shrikhande,et al. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors , 2021, The Journal of Nuclear Medicine.
[2] Yongmei Yin,et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.
[3] V. Mazzaferro,et al. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. , 2020, Annals of surgery.
[4] S. Dueland,et al. Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence. , 2020, Journal of hepatology.
[5] T. Hobday,et al. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights , 2020, OncoTargets and therapy.
[6] M. Falconi,et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] S. Truant,et al. ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry. , 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[8] O. Ciccarelli,et al. HBPD Table of Contents, Vol. 18, No. 5, 2019 , 2019, Digestive Surgery.
[9] W. Bechstein,et al. Surgical resection of neuroendocrine tumor liver metastases as part of multimodal treatment strategies: A propensity score matching analysis. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[10] T. Pawlik,et al. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms , 2018, Journal of Gastrointestinal Surgery.
[11] A. Vanoli,et al. Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study , 2018, Neuroendocrinology.
[12] G. Rindi,et al. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. , 2018, Endocrinology and metabolism clinics of North America.
[13] J. Ramage,et al. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. , 2018, Seminars in oncology.
[14] J. Berlin,et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] M. Marazuela,et al. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). , 2018, The oncologist.
[16] J. Mayerle,et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. , 2017, The lancet. Diabetes & endocrinology.
[17] Shouhao Zhou,et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.
[18] T. Pawlik,et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review , 2017, Surgery.
[19] E. Nakakura,et al. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society , 2017, Pancreas.
[20] J. Hainsworth,et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[22] D. Raptis,et al. Meta‐analysis of associating liver partition with portal vein ligation and portal vein occlusion for two‐stage hepatectomy , 2016, The British journal of surgery.
[23] L. Mariani,et al. The Long‐Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] V. Ambrosini,et al. Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[25] James C Yao,et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.
[26] E. Krenning,et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum , 2016, Neuroendocrinology.
[27] P. Ruszniewski,et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study , 2016, Endocrine-related cancer.
[28] E. Krenning,et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site , 2016, Neuroendocrinology.
[29] E. D. de Vries,et al. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Goldberg,et al. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes , 2015, Transplantation.
[31] V. Mazzaferro,et al. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[32] R. Schilsky,et al. Recommendations for management of patients with neuroendocrine liver metastases. , 2014, The Lancet. Oncology.
[33] G. Åkerström,et al. Indication for Liver Transplantation in Young Patients with Small Intestinal NETs Is Rare? , 2014, World Journal of Surgery.
[34] F. Pruvot,et al. Liver Transplantation for Neuroendocrine Tumors in Europe—Results and Trends in Patient Selection: A 213-Case European Liver Transplant Registry Study , 2013, Annals of surgery.
[35] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[36] D. Coppola,et al. First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.
[37] R. Jensen,et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.
[38] Manal M. Hassan,et al. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum , 2010, Pancreas.
[39] M. Choti,et al. Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis , 2010, Annals of Surgical Oncology.
[40] E. Baudin,et al. Hepatic Metastases From Neuroendocrine Tumors With a “Thin Slice” Pathological Examination: They are Many More Than You Think … , 2010, Annals of surgery.
[41] M. Falconi,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors , 2009, Neuroendocrinology.
[42] Kurinchi Selvan Gurusamy,et al. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. , 2009, The Cochrane database of systematic reviews.
[43] A. Bockisch,et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease , 2009, The British journal of surgery.
[44] Olga Ciccarelli,et al. Tacrolimus Monotherapy in Liver Transplantation: One-Year Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Study , 2008, Annals of surgery.
[45] G. Petersen,et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] V. Mazzaferro,et al. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? , 2007, Journal of hepatology.
[47] M. Choti,et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer , 2007, Journal of Gastrointestinal Surgery.
[48] I. Modlin,et al. A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.
[49] P. Brousse,et al. Split liver transplantation , 2002, Steinkopff.
[50] D. Canes,et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? , 2000, Journal of the American College of Surgeons.